AroCell AB (publ) (AROC.ST)
SEK 0.57
(0.0%)
SEK 0.57
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.24 Million SEK | -15.56% |
| 2022 | 13.31 Million SEK | 33.71% |
| 2021 | 9.96 Million SEK | 136.21% |
| 2020 | 4.21 Million SEK | -61.55% |
| 2019 | 10.96 Million SEK | 277.58% |
| 2018 | 2.9 Million SEK | 2.44% |
| 2017 | 2.83 Million SEK | -4.37% |
| 2016 | 2.96 Million SEK | 81.72% |
| 2015 | 1.63 Million SEK | -43.38% |
| 2014 | 2.88 Million SEK | 26.74% |
| 2013 | 2.27 Million SEK | 24.27% |
| 2012 | 1.83 Million SEK | -17.52% |
| 2011 | 2.21 Million SEK | -8.88% |
| 2010 | 2.43 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.4 Million SEK | 1.4% |
| 2024 Q2 | 12.83 Million SEK | 12.52% |
| 2024 Q3 | 13.04 Million SEK | 1.66% |
| 2023 Q4 | 11.24 Million SEK | 3.25% |
| 2023 FY | 11.24 Million SEK | -15.56% |
| 2023 Q3 | 10.89 Million SEK | -0.89% |
| 2023 Q2 | 10.99 Million SEK | -5.88% |
| 2023 Q1 | 11.67 Million SEK | -12.33% |
| 2022 Q4 | 13.31 Million SEK | 30.04% |
| 2022 FY | 13.31 Million SEK | 33.71% |
| 2022 Q3 | 10.24 Million SEK | -23.97% |
| 2022 Q2 | 13.47 Million SEK | -21.49% |
| 2022 Q1 | 17.15 Million SEK | 72.25% |
| 2021 Q1 | 3.72 Million SEK | -11.69% |
| 2021 Q4 | 9.96 Million SEK | -1.0% |
| 2021 Q2 | 5.33 Million SEK | 43.15% |
| 2021 Q3 | 10.06 Million SEK | 88.75% |
| 2021 FY | 9.96 Million SEK | 136.21% |
| 2020 Q2 | 3.91 Million SEK | 18.16% |
| 2020 Q1 | 3.31 Million SEK | -69.78% |
| 2020 FY | 4.21 Million SEK | -61.55% |
| 2020 Q3 | 3.56 Million SEK | -8.88% |
| 2020 Q4 | 4.21 Million SEK | 18.16% |
| 2019 Q3 | 3.57 Million SEK | 53.81% |
| 2019 Q4 | 10.96 Million SEK | 207.24% |
| 2019 Q2 | 2.32 Million SEK | -4.29% |
| 2019 Q1 | 2.42 Million SEK | -16.52% |
| 2019 FY | 10.96 Million SEK | 277.58% |
| 2018 Q2 | 2.65 Million SEK | -24.63% |
| 2018 FY | 2.9 Million SEK | 2.44% |
| 2018 Q4 | 2.9 Million SEK | 17.75% |
| 2018 Q3 | 2.46 Million SEK | -7.12% |
| 2018 Q1 | 3.52 Million SEK | 24.27% |
| 2017 Q4 | 2.83 Million SEK | 51.33% |
| 2017 FY | 2.83 Million SEK | -4.37% |
| 2017 Q1 | 2.23 Million SEK | -24.63% |
| 2017 Q2 | 3.55 Million SEK | 59.19% |
| 2017 Q3 | 1.87 Million SEK | -47.33% |
| 2016 FY | 2.96 Million SEK | 81.72% |
| 2016 Q1 | 2.09 Million SEK | 28.32% |
| 2016 Q4 | 2.96 Million SEK | -24.22% |
| 2016 Q3 | 3.91 Million SEK | 20.92% |
| 2016 Q2 | 3.23 Million SEK | 54.54% |
| 2015 Q3 | 3.38 Million SEK | 39.52% |
| 2015 FY | 1.63 Million SEK | -43.38% |
| 2015 Q4 | 1.63 Million SEK | -51.85% |
| 2015 Q1 | 1.28 Million SEK | -55.52% |
| 2015 Q2 | 2.42 Million SEK | 89.47% |
| 2014 Q4 | 2.88 Million SEK | 38.51% |
| 2014 Q3 | 2.08 Million SEK | 31.29% |
| 2014 FY | 2.88 Million SEK | 26.74% |
| 2014 Q2 | 1.58 Million SEK | -2.34% |
| 2014 Q1 | 1.62 Million SEK | -28.63% |
| 2013 Q3 | 1.46 Million SEK | -34.57% |
| 2013 Q4 | 2.27 Million SEK | 55.23% |
| 2013 FY | 2.27 Million SEK | 24.27% |
| 2013 Q1 | 1.78 Million SEK | -2.57% |
| 2013 Q2 | 2.23 Million SEK | 25.57% |
| 2012 Q4 | 1.83 Million SEK | -5.18% |
| 2012 Q3 | 1.93 Million SEK | -1.38% |
| 2012 Q1 | 2.43 Million SEK | 9.84% |
| 2012 FY | 1.83 Million SEK | -17.52% |
| 2012 Q2 | 1.95 Million SEK | -19.7% |
| 2011 FY | 2.21 Million SEK | -8.88% |
| 2011 Q4 | 2.21 Million SEK | -14.5% |
| 2011 Q3 | 2.59 Million SEK | -8.69% |
| 2011 Q2 | 2.84 Million SEK | 0.0% |
| 2010 Q4 | 2.43 Million SEK | 0.0% |
| 2010 FY | 2.43 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | 125 Million SEK | 91.003% |
| Immunovia AB (publ) | 31.69 Million SEK | 64.512% |
| Prostatype Genomics AB (publ) | 24.54 Million SEK | 54.188% |
| SenzaGen AB | 29.56 Million SEK | 61.966% |
| Spermosens AB | 13.41 Million SEK | 16.156% |